Compound Information | SONAR Target prediction |
Name: | CLINDAMYCIN HYDROCHLORIDE |
Unique Identifier: | SPE01500193 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | |
Molecular Weight: | 427.174 g/mol |
X log p: | 0.00899999999999979 (online calculus) |
Lipinksi Failures | 0 |
TPSA | 54.84 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 7 |
Rotatable Bond Count: | 8 |
Canonical Smiles: | Cl.CCCC1CC(N(C)C1)C(=O)NC(C(C)Cl)C1OC(SC)C(O)C(O)C1O |
Source: | semisynthetic; U-21251 |
Therapeutics: | antibacterial, inhibits protein synthesis |
Generic_name: | Clindamycin |
Chemical_iupac_name: | N-[2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl)-propyl]-1-met hyl-4-propyl-pyrrolidine-2-carboxamide |
Drug_type: | Approved Drug |
Pharmgkb_id: | PA449035 |
Kegg_compound_id: | C06914 |
Drugbank_id: | APRD00566 |
Melting_point: | 255 oC |
H2o_solubility: | 30.6 mg/L |
Logp: | 1.224 |
Cas_registry_number: | 18323-44-9 |
Drug_category: | Anti-bacterial Agents; Lincomycins; ATC:D10AF01; ATC:G01AA10; ATC:J01FF01 |
Indication: | For the treatment of serious infections caused by susceptible anaerobic bacteria (anaerobes, streptococci, pneumococci, and staphylococci) |
Pharmacology: | Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal. |
Mechanism_of_action: | Systemic/Vaginal-Clindamycin inhibits protein synthesis of bacteria by binding to the 50 S ribosomal subunits of the bacteria. Topical-Clindamycin reduces free fatty acid concentrations on the skin and to suppress the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles. |
Organisms_affected: | Enteric bacteria and other eubacteria |